Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDXNASDAQ:IMABNASDAQ:LENZNASDAQ:PRAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$3.72+0.5%$4.21$3.21▼$8.06$890.03M0.594.51 million shs6.86 million shsIMABI-Mab$2.58+3.6%$1.10$0.60▼$3.08$210.68M1.17356,452 shs509,826 shsLENZLENZ Therapeutics$29.58-1.4%$26.52$16.28▼$38.93$832.56M0.42190,517 shs228,051 shsPRAXPraxis Precision Medicines$45.03+1.0%$36.66$26.70▼$91.83$917.22M2.6388,793 shs269,809 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx-1.07%+0.27%+4.82%-31.73%-44.19%IMABI-Mab-5.68%+39.11%+163.49%+196.57%+33.87%LENZLENZ Therapeutics+6.84%+2.77%+2.15%+21.21%+58.14%PRAXPraxis Precision Medicines-2.73%+7.81%+16.09%+19.60%+13.20%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDXArdelyx3.9616 of 5 stars3.51.00.04.42.12.50.6IMABI-Mab3.3522 of 5 stars3.74.00.00.03.51.70.6LENZLENZ Therapeutics1.6781 of 5 stars3.61.00.00.02.80.80.0PRAXPraxis Precision Medicines2.5563 of 5 stars4.42.00.00.01.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 2.90Moderate Buy$10.39179.27% UpsideIMABI-Mab 3.33Buy$5.50113.18% UpsideLENZLENZ Therapeutics 3.17Buy$46.6057.54% UpsidePRAXPraxis Precision Medicines 2.80Moderate Buy$109.90144.06% UpsideCurrent Analyst Ratings BreakdownLatest IMAB, PRAX, ARDX, and LENZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025PRAXPraxis Precision MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.006/2/2025PRAXPraxis Precision MedicinesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform$97.005/8/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.005/7/2025PRAXPraxis Precision MedicinesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.005/5/2025PRAXPraxis Precision MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetUnderperform ➝ Underperform$26.00 ➝ $28.005/5/2025PRAXPraxis Precision MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/2/2025ARDXArdelyxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.005/2/2025ARDXArdelyxRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$11.005/1/2025PRAXPraxis Precision MedicinesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$105.00 ➝ $105.004/16/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/14/2025LENZLENZ TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$38.00 ➝ $51.00(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$361.71M2.46N/AN/A$0.73 per share5.10IMABI-Mab$3.27M64.37N/AN/A$2.93 per share0.88LENZLENZ TherapeuticsN/AN/AN/AN/A$22.06 per shareN/APRAXPraxis Precision Medicines$8.12M112.93N/AN/A$7.92 per share5.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$39.14M-$0.22N/A12.00N/A-11.73%-24.87%-10.51%7/30/2025 (Estimated)IMABI-Mab-$206.44MN/A0.00N/AN/AN/AN/AN/A8/27/2025 (Estimated)LENZLENZ Therapeutics-$124.65M-$1.77N/AN/AN/AN/A-58.48%-55.50%8/13/2025 (Estimated)PRAXPraxis Precision Medicines-$123.28M-$10.72N/AN/AN/A-9,409.22%-54.86%-50.52%8/12/2025 (Estimated)Latest IMAB, PRAX, ARDX, and LENZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025LENZLENZ Therapeutics-$0.55-$0.53+$0.02-$0.53N/AN/A5/2/2025Q1 2025PRAXPraxis Precision Medicines-$3.20-$3.29-$0.09-$3.29$0.20 millionN/A5/1/2025Q1 2025ARDXArdelyx-$0.10-$0.17-$0.07-$0.17$79.40 million$74.11 million3/19/2025Q4 2024LENZLENZ Therapeutics-$0.42-$0.46-$0.04-$0.46N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/AIMABI-MabN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx0.874.584.31IMABI-MabN/A15.9915.99LENZLENZ TherapeuticsN/A28.6328.63PRAXPraxis Precision MedicinesN/A10.9610.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%IMABI-Mab38.38%LENZLENZ Therapeutics54.32%PRAXPraxis Precision Medicines67.84%Insider OwnershipCompanyInsider OwnershipARDXArdelyx4.80%IMABI-Mab22.10%LENZLENZ Therapeutics6.90%PRAXPraxis Precision Medicines2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90239.26 million222.88 millionOptionableIMABI-Mab38081.66 million63.49 millionOptionableLENZLENZ Therapeutics11028.15 million16.94 millionN/APRAXPraxis Precision Medicines11020.37 million18.14 millionOptionableIMAB, PRAX, ARDX, and LENZ HeadlinesRecent News About These CompaniesNeedham & Company LLC Reaffirms Buy Rating for Praxis Precision Medicines (NASDAQ:PRAX)June 12 at 8:30 AM | marketbeat.comBank of America Corp DE Reduces Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)June 12 at 3:07 AM | marketbeat.comFormer head trader of Denver-based investing company pleads guilty to insider tradingJune 9 at 5:01 AM | finance.yahoo.comWeston man pleads guilty to insider trading offense that made him $220KJune 8, 2025 | stamfordadvocate.comPraxis Precision Medicines (NASDAQ:PRAX) Trading Up 7.6% - Here's WhyJune 5, 2025 | marketbeat.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 4, 2025 | globenewswire.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Sold by Wellington Management Group LLPJune 4, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Holdings Reduced by Squarepoint Ops LLCJune 4, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Rating of "Moderate Buy" by AnalystsJune 3, 2025 | americanbankingnews.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJune 3, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Coverage Initiated by Analysts at OppenheimerJune 2, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Stock Position Reduced by BNP Paribas Financial MarketsJune 1, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Trading Down 5.6% - Should You Sell?May 31, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Trading 4.3% Higher - Should You Buy?May 30, 2025 | marketbeat.comPolar Asset Management Partners Inc. Makes New Investment in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)May 28, 2025 | marketbeat.com9,948 Shares in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Purchased by Woodline Partners LPMay 28, 2025 | marketbeat.comVoloridge Investment Management LLC Buys 40,875 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)May 27, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Purchased by Millennium Management LLCMay 26, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Position Boosted by VR Adviser LLCMay 22, 2025 | marketbeat.comVelan Capital Investment Management LP Sells 50,666 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)May 21, 2025 | marketbeat.comSoleus Capital Management L.P. Sells 15,858 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)May 21, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMAB, PRAX, ARDX, and LENZ Company DescriptionsArdelyx NASDAQ:ARDX$3.72 +0.02 (+0.54%) As of 04:00 PM EasternArdelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.I-Mab NASDAQ:IMAB$2.58 +0.09 (+3.61%) As of 04:00 PM EasternI-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.LENZ Therapeutics NASDAQ:LENZ$29.58 -0.42 (-1.40%) As of 04:00 PM EasternLENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Praxis Precision Medicines NASDAQ:PRAX$45.03 +0.43 (+0.96%) As of 04:00 PM EasternPraxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
